Literature DB >> 15735123

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.

Derek L Dai1, Magdalena Martinka, Gang Li.   

Abstract

PURPOSE: Akt is a serine/threonine kinase that leads to stimulation of cell cycle progression, cell proliferation, and inhibition of apoptosis. To investigate the role of Akt in melanoma pathogenesis, we examined the expression of phospho-Akt (p-Akt; Ser-473) in melanocytic lesions at different stages and analyzed the correlations between the p-Akt expression level and clinicopathologic factors and patient survival. PATIENTS AND METHODS: We evaluated the p-Akt expression in 12 cases of normal nevi, 58 cases of dysplastic nevi, 170 cases of primary melanomas, and 52 cases of melanoma metastases using tissue microarray and immunohistochemistry.
RESULTS: Strong p-Akt expression was observed in 17%, 43%, 49%, and 77% of the biopsies in normal nevi, dysplastic nevi, primary melanoma, and melanoma metastases, respectively. Significant differences for p-Akt staining pattern were observed between normal nevi and primary melanomas (P < .05), and between primary melanomas and melanoma metastases (P < .001). Furthermore, our Kaplan-Meier survival curves showed that strong p-Akt expression is inversely correlated with both overall and disease-specific 5-year survival of patients with primary melanoma (P < .05 for both). Strikingly, our multivariate Cox regression analysis revealed that p-Akt is an independent prognostic factor in low-risk melanomas (thickness < or = 1.5 mm; relative risk, 6.44; 95% CI, 1.28 to 32.55; P = .018).
CONCLUSION: The expression of p-Akt increases dramatically with melanoma invasion and progression and is inversely correlated with patient survival. In addition, p-Akt may serve as an independent prognostic marker and help to identify those patients with low-risk melanomas who are at increased risk of death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735123     DOI: 10.1200/JCO.2005.07.168

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  114 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  MMP2 expression is a prognostic marker for primary melanoma patients.

Authors:  Anand Rotte; Magdalena Martinka; Gang Li
Journal:  Cell Oncol (Dordr)       Date:  2012-06-06       Impact factor: 6.730

3.  AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

Authors:  David A Kircher; Kirby A Trombetti; Mark R Silvis; Gennie L Parkman; Grant M Fischer; Stephanie N Angel; Christopher M Stehn; Sean C Strain; Allie H Grossmann; Keith L Duffy; Kenneth M Boucher; Martin McMahon; Michael A Davies; Michelle C Mendoza; Matthew W VanBrocklin; Sheri L Holmen
Journal:  Mol Cancer Res       Date:  2019-05-28       Impact factor: 5.852

Review 4.  Molecular targets in melanoma: time for 'ethnic personalization'.

Authors:  Shane Y Morita; Svetomir N Markovic
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

5.  BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Authors:  Supriya Gaitonde; Surya K De; Marianna Tcherpakov; Antimone Dewing; Hongbin Yuan; Megan Riel-Mehan; Stan Krajewski; Gavin Robertson; Maurizio Pellecchia; Ze'ev Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

6.  A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms.

Authors:  Rolando Perez-Lorenzo; Kamraan Z Gill; Che-Hung Shen; Feng X Zhao; Bin Zheng; Hans-Joachim Schulze; David N Silvers; Georg Brunner; Basil A Horst
Journal:  J Invest Dermatol       Date:  2013-11-28       Impact factor: 8.551

7.  PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Authors:  Yanlin Yu; Meng Dai; Andrew Lu; Ellen Yu; Glenn Merlino
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

8.  Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis.

Authors:  Zhengguang Li; Jun Wu; Changping Wu; Jingting Jiang; Xiao Zheng; Bin Xu; Min Li
Journal:  Oncol Lett       Date:  2012-07-06       Impact factor: 2.967

9.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

10.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.